# Novel Therapeutic Hypotheses for Neuroinflammation Resolution
## 1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
**Description:** Synthetic super-agonists of GPR32 (RvD1 receptor) could restore microglial phagocytic capacity for clearing protein aggregates and apoptotic neurons. Enhanced efferocytosis would break the cycle of failed clearance that perpetuates chronic neuroinflammation in neurodegeneration.
**Target:** GPR32 (CMKLR1) receptor and downstream PI3K/Akt signaling
**Supporting Evidence:** GPR32 activation promotes microglial M2 polarization (PMID: 27432871). Defective efferocytosis is central to AD pathology (PMID: 31740835). RvD1 enhances Aβ clearance in AD models (PMID: 28814792).
**Confidence:** 0.75
## 2. Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy
**Description:** Viral-mediated delivery of ALOX15 specifically to reactive astrocytes could restore endogenous LXA4 biosynthesis. This would reactivate the astrocytic resolution program, converting neurotoxic A1 astrocytes back to neuroprotective phenotypes while preserving blood-brain barrier integrity.
**Target:** ALOX15 (15-lipoxygenase) in astrocytes
**Supporting Evidence:** ALOX15 deficiency correlates with AD progression (PMID: 29625896). LXA4 promotes astrocytic neuroprotection (PMID: 25988525). Astrocyte-specific gene therapy shows promise (PMID: 33737753).
**Confidence:** 0.68
## 3. Mitochondrial SPM Synthesis Platform Engineering
**Description:** Engineered mitochondria containing optimized SPM biosynthetic machinery could be delivered to microglia via nanoparticles. These "resolvin factories" would provide sustained local production of pro-resolving mediators at sites of neuroinflammation, bypassing systemic limitations.
**Target:** Mitochondrial ALOX5, ALOX12, ALOX15 enzyme cascades
**Supporting Evidence:** Mitochondrial dysfunction impairs SPM synthesis (PMID: 31358969). Mitochondrial transplantation shows neuroprotection (PMID: 32024967). SPM deficiency correlates with neurodegeneration severity (PMID: 30952852).
**Confidence:** 0.55
## 4. Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
**Description:** Cell-penetrating peptide mimetics of NPD1/PD1 could specifically target oligodendrocytes to resolve myelin-associated inflammation. These mimetics would activate the oligodendrocyte resolution program, promoting myelin repair while suppressing microglia-mediated demyelination.
**Target:** NPD1/PD1 receptors on oligodendrocytes (GPR37, potential novel receptors)
**Supporting Evidence:** NPD1 promotes oligodendrocyte survival (PMID: 24837704). Myelin debris triggers chronic neuroinflammation (PMID: 28179640). Resolution failure underlies multiple sclerosis pathology (PMID: 29180471).
**Confidence:** 0.62
## 5. Blood-Brain Barrier SPM Shuttle System
**Description:** Engineered transferrin receptor-targeting nanocarriers loaded with stable SPM analogs could bypass the blood-brain barrier's exclusion of endogenous resolvins. This shuttle system would deliver therapeutic concentrations of pro-resolving mediators directly to neuroinflammatory foci.
**Target:** Transferrin receptor (TFRC) for BBB crossing, multiple SPM receptors centrally
**Supporting Evidence:** SPMs poorly cross the BBB (PMID: 28860987). Transferrin receptor shuttles enable CNS drug delivery (PMID: 32041746). SPM deficiency is systemic in neurodegeneration (PMID: 31043226).
**Confidence:** 0.71
## 6. Circadian-Gated Maresin Biosynthesis Amplification
**Description:** Chronotherapeutic activation of maresin biosynthesis during natural resolution phases (early morning) could restore circadian inflammation resolution. Time-restricted delivery of MaR1 precursors or ALOX12 activators would work with endogenous circadian machinery to enhance resolution efficiency.
**Target:** ALOX12 and circadian clock proteins (CLOCK, BMAL1) interaction
**Supporting Evidence:** Circadian disruption impairs resolution (PMID: 30061532). MaR1 shows circadian variation (PMID: 29180506). Chronotherapy enhances anti-inflammatory efficacy (PMID: 31794686).
**Confidence:** 0.59
## 7. Senescent Microglia Resolution via Maresins-Senolytics Combination
**Description:** Combined treatment with maresin analogs plus selective senolytic agents could eliminate senescent microglia while simultaneously activating resolution programs in remaining cells. This dual approach would clear inflammatory "zombie" cells while restoring healthy microglial function.
**Target:** Senescent microglia (BCL-2 family, p16/p21 pathways) plus GPR18 (MaR1 receptor)
**Supporting Evidence:** Senescent microglia drive neurodegeneration (PMID: 33208946). Senolytics improve cognitive function (PMID: 31835026). MaR1 promotes microglial resolution phenotype (PMID: 29180477).
**Confidence:** 0.66